Novel selective malaria therapy developed
The GSK produced molecule, TCMDC-135051, has been found to be an effective and selective inhibitor of PfCLK3 – a protein essential to the lifecycle of malaria.
Please sign in or register for FREE
Sign in to RxNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Future Medicinal Chemistry FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RxNet account also gives you access to communities on regenerative medicine, real-world evidence and 3D printing in medicine. Find out more>>